Hims & Hers Health, Inc. (NYSE:HIMS - Get Free Report) COO Melissa Baird sold 33,337 shares of the stock in a transaction on Wednesday, April 9th. The stock was sold at an average price of $27.32, for a total value of $910,766.84. Following the transaction, the chief operating officer now directly owns 805,083 shares in the company, valued at approximately $21,994,867.56. This represents a 3.98 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.
Melissa Baird also recently made the following trade(s):
- On Wednesday, March 26th, Melissa Baird sold 67,687 shares of Hims & Hers Health stock. The shares were sold at an average price of $34.84, for a total value of $2,358,215.08.
- On Wednesday, February 12th, Melissa Baird sold 67,687 shares of Hims & Hers Health stock. The shares were sold at an average price of $44.71, for a total value of $3,026,285.77.
- On Tuesday, January 21st, Melissa Baird sold 67,687 shares of Hims & Hers Health stock. The stock was sold at an average price of $29.35, for a total transaction of $1,986,613.45.
Hims & Hers Health Stock Down 9.2 %
HIMS opened at $26.79 on Friday. The firm has a market capitalization of $5.95 billion, a P/E ratio of 60.88 and a beta of 1.65. The firm's 50 day moving average is $39.04 and its 200-day moving average is $30.30. Hims & Hers Health, Inc. has a 52-week low of $11.20 and a 52-week high of $72.98.
Hims & Hers Health (NYSE:HIMS - Get Free Report) last issued its quarterly earnings data on Monday, February 24th. The company reported $0.11 EPS for the quarter, topping analysts' consensus estimates of $0.09 by $0.02. The firm had revenue of $481.14 million for the quarter, compared to analyst estimates of $494.56 million. Hims & Hers Health had a net margin of 8.19% and a return on equity of 10.97%. Equities analysts expect that Hims & Hers Health, Inc. will post 0.29 earnings per share for the current fiscal year.
Analyst Upgrades and Downgrades
Several equities analysts recently commented on the stock. Bank of America upped their price target on shares of Hims & Hers Health from $21.00 to $22.00 and gave the stock an "underperform" rating in a research report on Tuesday, March 18th. Citigroup reaffirmed a "sell" rating on shares of Hims & Hers Health in a research report on Wednesday, April 2nd. Piper Sandler boosted their price target on Hims & Hers Health from $24.00 to $35.00 and gave the company a "neutral" rating in a research report on Tuesday, February 25th. Needham & Company LLC upped their price target on Hims & Hers Health from $31.00 to $61.00 and gave the stock a "buy" rating in a research note on Tuesday, February 25th. Finally, Canaccord Genuity Group lifted their price objective on Hims & Hers Health from $38.00 to $68.00 and gave the company a "buy" rating in a research note on Wednesday, February 19th. Two investment analysts have rated the stock with a sell rating, seven have given a hold rating and five have issued a buy rating to the company. According to MarketBeat.com, Hims & Hers Health presently has an average rating of "Hold" and an average target price of $38.25.
Read Our Latest Stock Analysis on HIMS
Institutional Inflows and Outflows
A number of institutional investors and hedge funds have recently bought and sold shares of the business. SlateStone Wealth LLC raised its position in shares of Hims & Hers Health by 4.0% in the 4th quarter. SlateStone Wealth LLC now owns 10,640 shares of the company's stock valued at $257,000 after purchasing an additional 413 shares in the last quarter. Blume Capital Management Inc. raised its holdings in Hims & Hers Health by 100.0% in the fourth quarter. Blume Capital Management Inc. now owns 1,200 shares of the company's stock valued at $29,000 after acquiring an additional 600 shares in the last quarter. Summit Investment Advisors Inc. boosted its stake in Hims & Hers Health by 3.3% during the 4th quarter. Summit Investment Advisors Inc. now owns 19,853 shares of the company's stock valued at $480,000 after acquiring an additional 628 shares during the last quarter. Cim LLC grew its holdings in Hims & Hers Health by 1.0% during the 4th quarter. Cim LLC now owns 71,869 shares of the company's stock worth $1,738,000 after acquiring an additional 694 shares in the last quarter. Finally, Harbour Investments Inc. increased its position in shares of Hims & Hers Health by 18.8% in the 4th quarter. Harbour Investments Inc. now owns 5,269 shares of the company's stock worth $127,000 after purchasing an additional 833 shares during the last quarter. Hedge funds and other institutional investors own 63.52% of the company's stock.
Hims & Hers Health Company Profile
(
Get Free Report)
Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to contact@insidertrades.com.
